arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Krystal Biotech, Inc.

KRYS
$351.13 ▲ +17.40 (+5.21%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
37 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
85
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Krystal Biotech, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $10.4B
Dividend Yield
Revenue Growth 24.1%
Op. Margin 49.0%
ROIC 3.6%
FCF / Share $2.41
Trailing P/E 189.8x
Price / Book 7.7x
FCF Yield 0.7%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

37-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$119.22M
↑ +24.1%
Net Income Profit after all expenses
$55.93M
↑ +56.5%
Operating Margin Operating profit as % of sales
49.0%
↑ +6.2% 94th
FCF / Share Free cash flow per share
$2.41
↓ -3.5%
Long-Term Debt Long-term obligations
$4.25M
— 0.0%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
97
Returns
83
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 37 quarters